PDCD1 and ovarian cancer: Moreover, in the phase 2 TOPACIO trial, niraparib and anti-PD-1 combination therapy has demonstrated clinical benefit in a broad patient population including patients with the hard-to-treat BRCA wild-type platinum-resistant cancers and platinum-refractory ovarian cancers (2017 SGO Abstract#2990).